Abstract
Since 2000, our ability to measure systemic lupus erythematosus (SLE) from a diagnostic, assessment, and prognostic standpoint has advanced substantially. These advances include the incorporation of the SLE Disease Activity Index, the British Isles Lupus Assessment Group, and their composite indices in clinical trials. Additional benchmarks, such as the Definition of Remission in SLE (DORIS) framework and lupus low disease activity state (LLDAS), have been used to evaluate disease activity and attainment of remission.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
